Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...

Severe obesity is already a significant problem for many children, especially since obese children often become obese adults.

The lauded Lasker Awards, frequently tied to Nobel Prize acclaim, highlighted the significant accomplishments of three ...

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the ...

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...

Weight reduction at one year linked to medication active agent, dosage, treatment indication, persistence of coverage ...